Business
Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development
SAN DIEGO, April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development
About this update from Fate Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, April 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Yu-Waye (Wayne) Chu, M.D. has joined the Company as Vice President, Clinical Development. Dr. Chu brings extensive experience in the development of cancer immunotherapies from Genentech, a member of the Roche Group, where he most recently served in Product Development Oncology as global development leader of mosunetuzumab, a full-length T cell-dependent bispecific CD20/CD3 antibody. Dr. Chu will be responsible for leading clinical development of the Company's induced pluripotent stem cell (iPSC)-derived, cell-based cancer immunotherapy programs.\"Wayne brings to Fate Therapeutics the passion, innovative spirit and hands-on clinical leadership necessary to bring new therapeutic modalities and first-in-kind cancer immunotherapies to patients,\" said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. \"Our first off-the-shelf, iPSC-derived NK cell product candidates, FT500 and FT516, have been specifically designed to augment the anti-cancer activity of checkpoint inhibitor and targeted antibody therapies, and Wayne's drug development and approval experience over the past 10 years with these types of immunotherapies in both liquid and solid tumors serves as a strong foundation for guiding our clinical development strategy.\"\"This is such an exciting time to join Fate Therapeutics as the first-ever iPSC-derived cancer immunotherapy FT500 is being delivered to patients and as the Company's rich pipeline of off-the-shelf, iPSC-derived NK cell and T-cell product candidates advances toward clinical investigation,\" said Dr. Chu. \"The first generation of patient-specific cellular immunotherapies have revolutionized the treatment of certain late-stage hematologic malignancies, and next-generation off-the-shelf approaches where cell products can be delivered ‘on demand', in repeat cycles, and earlier in disease progression, including in combination with well-established immune-oncology agents such as checkpoint inhibitor blockade and monoclonal antibody therapy, have the promise to change patient outcomes across the entire cancer field. I look forward to accelerating ...